Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands
about
Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agentsUnderstanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule InhibitorsTriple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutationPulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell linesA phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.Hepatocyte growth factor/MET in cancer progression and biomarker discoveryMolecular basis of drug resistance: epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors.Acquired resistance to TKIs in solid tumours: learning from lung cancer.Hepatocyte growth factor and Met in drug discovery.Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung.Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.One-step nucleic acid amplification (OSNA): where do we go with it?Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations.Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.EGFR-TKIs resistance via EGFR-independent signaling pathways.Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1
P2860
Q27027957-D023E69A-10EB-4137-AADE-B58976615EB0Q28546245-D0D7E652-F3AB-448F-9D3E-00E3CCD6AB1DQ34041747-C85C2B16-4C1A-4B68-9B2C-84A29385CFCEQ34404209-9108AD11-DA49-4395-B005-1AD28F0148E1Q34729796-9172F159-4AF0-4E7B-9713-94C96120D214Q36545596-1672B6F0-A467-495E-93B5-EE6A9E398A6EQ37222790-A14A074A-7712-4D96-B428-F4C9ABE148CFQ37735624-B41FD79E-B26E-4384-8428-51F101FEFC6AQ38172148-FF6134B1-4776-42CB-8890-2FC7EF90BEA6Q38224967-3BFC95B5-DBE5-43BA-974D-8D3B9CE468ABQ38377273-98BCD6B3-8812-46B6-89E1-698606820826Q38390024-91DD64D8-AB4E-4256-967E-F91A2AA45140Q38463905-C1F41AAD-FCD9-4332-8D70-F1C4C9B8297FQ38828914-3FC3680E-570F-4AE0-A938-825C58E58324Q38911597-3760EFFC-69DD-47BD-8159-EC85EEE3378CQ38941704-CF75D510-A49C-4CE0-9AF0-297091B95148Q41345101-BDED2659-130A-4CE9-A006-2FE1A40B4008Q47124054-6B83E60B-5D84-491F-A9EA-7909A95E1869Q49887890-30E275AD-2F3F-4429-BB09-C94FC9D4D258Q49887930-749E38E5-DEFE-4C6E-ADB3-265DB1FC5334Q58732696-652E0C00-6E18-4BBC-9FAF-8DEDAE86AA88
P2860
Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Ligand-triggered resistance to ...... growth factor receptor ligands
@ast
Ligand-triggered resistance to ...... growth factor receptor ligands
@en
Ligand-triggered resistance to ...... growth factor receptor ligands
@nl
type
label
Ligand-triggered resistance to ...... growth factor receptor ligands
@ast
Ligand-triggered resistance to ...... growth factor receptor ligands
@en
Ligand-triggered resistance to ...... growth factor receptor ligands
@nl
prefLabel
Ligand-triggered resistance to ...... growth factor receptor ligands
@ast
Ligand-triggered resistance to ...... growth factor receptor ligands
@en
Ligand-triggered resistance to ...... growth factor receptor ligands
@nl
P2093
P2860
P3181
P1433
P1476
Ligand-triggered resistance to ...... growth factor receptor ligands
@en
P2093
Seiji Yano
Shinji Takeuchi
Tadaaki Yamada
Takayuki Nakagawa
P2860
P304
P3181
P356
10.1111/J.1349-7006.2012.02279.X
P407
P577
2012-07-01T00:00:00Z